Reporte Anual
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Reportes Previos Al 2T21 12 De Julio De 2021
COMPARATIVOS TRIMESTRALES Reportes Previos al 2T21 12 de Julio de 2021 • Esperamos un 2T21 con reportes positivos para las empresas del IPyC. Carlos A. González Tabares • Estimamos crecimiento en Ventas y Ebitda de 10.1% y 20.8% respectivamente. • Las Ganadoras: Asur, Gap, Gcarso, Peñoles y Pinfra. Reportes al 2T21: Crecimiento en Ventas y Ebitda de 10.1% y 20.8% respectivamente. Una vez concluido el 2T21, las empresas que cotizan en Bolsa tendrán para reportar sus resultados financieros hasta el próximo 28 de Julio. Para las empresas de la muestra del S&P’s/BMV/IPyC estimamos reportes positivos, con un crecimiento estimado en Ventas, Ebitda y Utilidad Neta de 10.1%, 20.8% y 223.3% respectivamente. La mediana de crecimiento para nuestra muestra de más de 50 emisoras, a nivel de Ventas, Ebitda y Resultado Neto es de 12.0%, 13.9% y 18.3% respectivamente. Recuperación moderada. Durante el 2T21 los resultados de las empresas que cotizan se verán altamente favorecidos, con crecimientos de doble y hasta triple dígito, ante la mayor movilidad y reapertura de actividades, el avance en el proceso de vacunación tanto a nivel local como internacional, la fuerte recuperación económica en EUA ante los elevados estímulos económicos, y una base de comparación baja respecto al mismo periodo del año anterior, cuando iniciaban las más estrictas medidas de confinamiento. A pesar de los buenos resultados esperados, será importante comparar las cifras reportadas respecto a los niveles pre-pandemia para identificar el grado de recuperación. Empresas del sector de aeropuertos, materias primas y del sector industrial, serán las más beneficiadas en este periodo. -
Prevé Banxico Crecimiento De 6.2% En 2021
RETIRO COMPLETO EN 2024 DICE AMLO QUE CANCELARÍA FACE, TWITTER Y HARÍA SU LIBRO O R U EN PALENQUE. SC PÁG. 30 TO AR U C AÑO XL Nº10954 · CIUDAD DE MÉXICo · jUEVES 30 DE SEPTIEMBRE DE 2021 · $10 M.N. · elfinanciero.com.mx Ansiedad en mercados pone RA VI A T S OLÁ C presión al peso NI ADÁN AUGUSTO. Reitera disposición a construir acuerdos con la oposición. EU. Aprueba la Cámara baja ley para suspender techo de endeudamiento; prevén fracaso en el Senado Segob: México ‘no Una mayor percepción de riesgo en los mercados fortaleció ayer al dó- Dólar interbancario Cierre diario en pesos por divisa merece un clima lar y debilitó al peso, que en las úl- 20.8 timas cinco jornadas acumuló una 20.63 20.59 pérdida de 3.1 por ciento, aunque 20.42 de crispación’ analistas esperan que una posible 20.19 alza en la tasa de referencia que “El país no se merece un clima de “pero soy parte de un gobierno hoy anunciaría Banxico, de 4.5 a crispación, pero es responsabili- que no acepta regalos ni canon- 19.87 4.75 por ciento, le dé un respiro. 19.6 dad de todos”, dijo el secretario jías. Somos distintos”. El peso cedió 1.1 por ciento, al 18 JUN 21 JUL 20 AGO 10 SEP 29 SEP de Gobernación, Adán Augusto En el marco de la Glosa del III cerrar el dólar en 20.59 unidades, López, en su comparecencia ante Informe de Gobierno ofreció a la según Banxico. Esta ansiedad tam- 2021 el pleno del Senado, en la que la oposición “puertas abiertas”. -
Amgen 2008 Annual Report and Financial Summary Pioneering Science Delivers Vital Medicines
Amgen 2008 Annual Report and Financial Summary Pioneering science delivers vital medicines About Amgen Products Amgen discovers, develops, manufactures Aranesp® (darbepoetin alfa) and delivers innovative human therapeutics. ® A biotechnology pioneer since 1980, Amgen Enbrel (etanercept) was one of the fi rst companies to realize ® the new science’s promise by bringing EPOGEN (Epoetin alfa) safe and effective medicines from the lab Neulasta® (pegfi lgrastim) to the manufacturing plant to patients. NEUPOGEN® (Filgrastim) Amgen therapeutics have changed the practice of medicine, helping millions of Nplate® (romiplostim) people around the world in the fi ght against ® cancer, kidney disease, rheumatoid Sensipar (cinacalcet) arthritis and other serious illnesses, and so Vectibix® (panitumumab) far, more than 15 million patients worldwide have been treated with Amgen products. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. 0405 06 07 08 0405 06 07 08 0405 06 07 08 0405 06 07 08 Total revenues “Adjusted” earnings Cash fl ow from “Adjusted” research and ($ in millions) per share (EPS)* operations development (R&D) expenses* (Diluted) ($ in millions) ($ in millions) 2008 $15,003 2008 $4.55 2008 $5,988 2008 $2,910 2007 14,771 2007 4.29 2007 5,401 2007 3,064 2006 14,268 2006 3.90 2006 5,389 2006 3,191 2005 12,430 2005 3.20 2005 4,911 2005 2,302 2004 10,550 2004 2.40 2004 3,697 2004 1,996 * “ Adjusted” EPS and “adjusted” R&D expenses are non-GAAP fi nancial measures. See page 8 for reconciliations of these non-GAAP fi nancial measures to U.S. -
AILERON THERAPEUTICS, INC. (Name of Registrant As Specified in Its Charter)
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 AILERON THERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ☐ Fee paid previously with preliminary materials. ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount previously paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Table of Contents AILERON THERAPEUTICS, INC. -
UNITED STATES SECURITIES and EXCHANGE COMMISSION Form
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☒ 1934 For the fiscal year ended December 31, 2008 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ☐ OF 1934 Commission file number 000-12477 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) One Amgen Center Drive, 91320-1799 Thousand Oaks, California (Zip Code) (Address of principal executive offices) (805) 447-1000 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(g) of the Act: Common stock, $0.0001 par value; preferred share purchase rights (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. -
Annual-Report-Mexichem-2018-Fv---En
*Notice: this document is an English translation of a Spanish-language document and is provided for information purposes only. In the event of any discrepancy, the text of the original Spanish- language document shall prevail. The Spanish-language document is available on the following websites: www.orbia.com/en/investor-relations/ and www.bmv.com.mx ANNUAL REPORT 2018 SUBMITTED PURSUANT TO THE GENERAL PROVISIONS APPLICABLE TO ISSUERS OF SECURITIES AND OTHER MARKET PARTICIPANTS FOR THE YEAR ENDING DECEMBER 31, 2018 MEXICHEM, S.A.B. de C.V. Figures in millions of U.S. dollars ($) Río San Javier No. 10 Viveros del Río 54060, Tlalnepantla de Baz, Estado de México Tel. 5366 4000 Fax 5397 8836 Mexichem S.A.B. de C.V. securities listed on the Bolsa Mexicana de Valores, S.A.B. de C.V. (Mexican Stock Exchange). I. Mexichem, S.A.B. de C.V. lists Series One, Class "I" and "II" shares representing the fixed part of its capital stock without right of withdrawal and the variable part of its capital stock, respectively. The shares confer the same corporate and patrimonial rights to their holders. Ticker Symbol: MEXCHEM* The MEXCHEM "*" Series shares are registered in the National Securities Registry (RNV - acronym in Spanish) and are listed on the Bolsa Mexicana de Valores, S.A.B. de C.V. The credit risk rating assigned to the MEXCHEM "*" Series shares by Standard & Poor is 'BBB-' on a global scale and 'mxAA/mxA-1+ on a national scale with a stable outlook, by Fitch Ratings is 'BBB' on a global scale and 'AA+' (mex) on a long-term national scale with a stable outlook, and by Moody's is 'Baa3' on a global scale. -
Orbia Announces Cash Tender Offer for Its Outstanding Notes Due 2022
Stock Information Mexican Stock Exchange Ticker: Orbia* Orbia Announces Cash Tender Offer for Its Outstanding Notes Due 2022 MEXICO CITY, Mexico; May 17, 2021 – Orbia Advance Corporation, S.A.B. de C.V. (“Orbia”) (BMV: ORBIA) announces that it has commenced an offer to purchase its outstanding US$750,000,000 principal amount of 4.875% Senior Notes due 2022 (CUSIP/ISIN: 59284BAB4; P57908AD0 / US59284BAB45; USP57908AD01) (the “Securities”) pursuant to an offer (the “Tender Offer”) to purchase for cash any and all of the Securities on the terms and subject to the conditions set forth in the offer to purchase, dated May 17, 2021 (the “Offer to Purchase”) and the related notice of guaranteed delivery (the “Notice of Guaranteed Delivery” and, together with the Offer to Purchase, the “Offer Documents”). The Tender Offer will expire at 5:00 p.m. (New York City time) on May 21, 2021, unless extended (such date and time, as the same may be extended, the “Expiration Date”). Securities validly tendered may be withdrawn at any time at or prior to 5:00 p.m. (New York City time) on May 21, 2021, unless extended, but not thereafter. The settlement date of the Tender Offer will be promptly following the Expiration Date, expected to be no later than three business days following the Expiration Date, or May 26, 2021, unless extended (such date, as the same may be extended, the “Settlement Date”). Holders of Securities who (i) validly tender their Securities on or prior to the Expiration Date or (ii) deliver a properly completed and duly executed Notice of Guaranteed Delivery at or prior to the Expiration Date and tender their Securities at or prior to 5:00 p.m. -
Pharmaceutical Settlements
Drug Patent Settlements Between Rivals: A Survey C. Scott Hemphill Columbia Law School Working paper available at ssrn.com/abstract=969492 March 12, 2007 Electronic copy of this paper is available at: http://ssrn.com/abstract=969492 Drug Patent Settlements Between Rivals: A Survey C. Scott Hemphill* Introduction .......................................................................................................................................... 3 I. Settlements in summary ........................................................................................................... 5 II. The mechanisms of payment for delay................................................................................. 13 A. Compensation to the generic firm............................................................................... 14 1. Cash and overpayment...................................................................................... 14 2. Preserving exclusivity........................................................................................ 16 3. Underpricing....................................................................................................... 18 4. Additional channels........................................................................................... 19 B. Delay in generic entry................................................................................................... 20 1. Neutralizing the first filer ................................................................................. 20 2. Bottleneck -
HSBC Global Investment Funds MEXICO EQUITY Monthly Report 31 August 2021 | Share Class AC
HSBC Global Investment Funds MEXICO EQUITY Monthly report 31 August 2021 | Share class AC Share Class Details Investment objective Key metrics The Fund aims to provide long term capital growth and income by investing in a portfolio of NAV per Share USD 7.96 Mexican shares. Performance 1 month 2.20% Volatility 3 years 27.97% Investment strategy Fund facts UCITS V compliant Yes In normal market conditions, the Fund will invest at least 90% of its assets in shares (or securities similar to shares) of companies of any size, that are based in, or carry out most of their business Dividend treatment Accumulating in Mexico. The Fund may invest up to 10% of its assets in other funds, including HSBC funds. Dealing frequency Daily See the Prospectus for a full description of the investment objectives and derivative usage. Valuation Time 17:00 Luxembourg Share Class Base Currency USD Main risks Domicile Luxembourg • The Fund's unit value can go up as well as down, and any capital invested in the Fund may Inception date 28 February 2013 be at risk. Fund Size USD 34,816,687 • The value of investible securities can change over time due to a wide variety of factors, Reference 100% MSCI Mexico 10/40 including but not limited to: political and economic news, government policy, changes in benchmark IMI Net demographics, cultures and populations, natural or human-caused disasters etc. • The Fund may invest in Emerging Markets, these markets are less established, and often Managers Philippe Pequignot more volatile, than developed markets and involve higher risks, particularly market, liquidity Fees and expenses and currency risks. -
Las Favoritas De La BMV… 17 De Agosto De 2021
LAS FAVORITAS DE BMV Las Favoritas de la BMV… 17 de Agosto de 2021 J. Roberto Solano • Este reporte incluye recomendaciones de inversión entre una muestra que incluye las Brian Rodríguez 66 empresas más importantes de la BMV. Cesar A. Salinas • En esta ocasión recomendamos participar en PEÑOLES, PINFRA, GMEXICO, LIVEPOL, ORBIA, ALSEA, FEMSA, KOF, GAP y LACOMER. Las Favoritas de la BMV En este reporte estamos haciendo la sugerencia para participar en algunas emisoras que cotizan en la BMV (Bolsa Mexicana de Valores), con especial atención a las 66 emisoras más importantes de este universo. Por el momento, las empresas pertenecen principalmente a los sectores de Aeropuertos, Aerolíneas, Alimentos, Autoservicios, Bancos, Comunicaciones, Construcción, Consumo, Fibras, Hotelero, Infraestructura, entre otros. Metodología de Selección Nuestra selección de emisoras se fundamenta con base en los siguientes criterios de selección: 1) Un estimado de rendimiento por consenso en términos “absolutos”, es decir, no considera un rendimiento relativo a un Benchmark (IPyC); 2) Las recomendaciones de inversión se dan de manera individual, no necesariamente como un portafolio de inversión, por lo que no incluye una diversificación en términos de tamaño, sector o “peso” dentro un índice; y 3) La selección de emisoras contempla una calificación sobre los criterios de potencial de rendimiento 2021, expectativas de crecimiento para 2021, resultados trimestrales, valuación, apalancamiento y tendencia (aspecto técnico). Adicionalmente, incluimos un factor cualitativo referente a noticias corporativas recientes, indicadores económicos o una coyuntura en particular. ¿Qué Emisoras Sugerimos? Las emisoras en las que sugerimos participar son las siguientes: Industrias Peñoles, Pinfra, Grupo México, Liverpool, Orbia, Alsea, Femsa, Kof, Gap y Lacomer. -
2021 Mayo 10
2021 Mayo 10 Economía mexicana Sin cambios. Banco de México dejará sin cambios la tasa de interés de referencia en la reunión de esta semana, pero discutirá al menos dos temas. El importante desvío de inflación de abril respecto a la trayectoria fijada, y La situación de los mercados financieros mundiales. Ambos, en esencia, no son factores de preocupación, por el momento. Perspectiva semanal Inversión fija bruta (feb. 2021, -3.2%). Cae nuevamente en su variación anual, aunque mostrando un importante avance en el margen. Producción Industrial (Mar. 2021, 0.6%). Finalmente se ubica en terreno positivo a tasa anual. Manufactura habría mejorado. Decisión de política monetaria. No esperamos cambios en la tasa de referencia local. Se mantendrá en 4 por ciento. Atentos al tono y contenido del comunicado de prensa. Lo que hay que saber de la semana que concluye. Inflación de abril en México. Economía internacional. Semana con datos laborales muy decepcionantes en EEUU y turbulencias políticas en América Latina. En cuanto a la política monetaria, los bancos centrales escogen trayectorias cada vez más individualizadas. Finalmente, inició el debate acerca de la potencial liberación de los patentes de las vacunas contra COVID, después de que Biden se expresó a favor. Renta Variable El IPC alcanza su mejor nivel desde septiembre de 2018. En México el índice S&P BMV IPC cerró la semana en 49,249 unidades registrando un avance respecto al viernes previo de +2.58% en MXN, y de +4.28% en USD. En lo que va de 2021, el índice S&P BMV IPC acumula un avance de +11.76% en MXN y un incremento de +11.74% en USD. -
Healthcare Conference
25th Annual HEALTHCARE CONFERENCE Healthcare Westin St. Francis San Francisco January 8–11, 2007 JPMorgan cordially invites you to attend the 25th Annual Healthcare Conference, January 8 –11, 2007, at the Westin St. Francis in San Francisco. JPMorgan’s premier conference on the healthcare industry will feature more than 260 public and private companies over four days of simultaneous sessions. In addition, the conference will host topical panel discussions featuring leading industry experts. Preliminary List of Invited Presenting Companies Actelion Ltd Baxter International Inc. Cooper Companies Aetna Incorporated BD (Becton, Dickinson) Coventry Affymetrix, Inc. Beckman Coulter, Inc. Dade Behring Holdings, Inc. Alcon, Inc. Bioenvision, Inc. DaVita Inc. Align Technology, Inc. Biogen Idec deCODE genetics, Inc. Allscripts Healthcare Solutions Inc. Biomet, Inc. Digene Altana Boston Scientific Corporation Digirad Corporation — US American Medical Systems Holdings Inc. Bristol-Myers Squibb Company Diversa Corporation Amerigroup Corp. Cambrex Corporation DJO Incorporated AmerisourceBergen Cardinal Health, Inc. Dyax Corp. Amgen, Inc. Caremark Rx, Inc. Eclipsys Corporation AMN Healthcare Services, Inc. Celgene Corporation Edwards Lifesciences Corporation AmSurg Corporation Cell Genesys Elan Corporation, plc Anadys Pharmaceuticals CENTENE Corporation Eli Lilly and Company Applied Biosystems Group Cephalon, Inc. Emdeon Ariad Pharmaceuticals, Inc. Cerner Corporation Emergency Medical Services Corporation AstraZeneca Group plc Charles River Laboratories,